Hyperprogression in NSCLC Patients With PD-1/PD-L1 Inhibitors

A study shows hyperprogressive disease (HPD) occurred more commonly among patients with pretreated non-small cell lung cancer (NSCLC) receiving PD-1/PD-L1 inhibitors.

Source: CancerNetwork - September 21, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news